Literature DB >> 31436845

Binimetinib in heavily pretreated patients with NRAS-mutant melanoma with brain metastases.

S M Goldinger1, A Valeska Matter1, U Urner-Bloch2, J Narainsing1, S Micaletto1, I Blume3, J Mangana1, R Dummer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31436845     DOI： 10.1111/bjd.18449

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  3 in total

Review 1.  Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.

Authors:  Ayal A Aizer; Nayan Lamba; Manmeet S Ahluwalia; Kenneth Aldape; Adrienne Boire; Priscilla K Brastianos; Paul D Brown; D Ross Camidge; Veronica L Chiang; Michael A Davies; Leland S Hu; Raymond Y Huang; Timothy Kaufmann; Priya Kumthekar; Keng Lam; Eudocia Q Lee; Nancy U Lin; Minesh Mehta; Michael Parsons; David A Reardon; Jason Sheehan; Riccardo Soffietti; Hussein Tawbi; Michael Weller; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2022-10-03       Impact factor: 13.029

Review 2.  Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents.

Authors:  Stergios J Moschos
Journal:  Am J Clin Dermatol       Date:  2022-05-09       Impact factor: 6.233

3.  Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy.

Authors:  Aaron G Issac; David Szafron; Dongguang Wei; Jennifer L McQuade; Yinghong Wang
Journal:  Case Rep Gastroenterol       Date:  2022-06-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.